DUBLIN, Ireland and LONDON, England, October 11 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (“Alltracel”, or “the Company”), (AIM:AP.L), the Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets is pleased to confirm Q3 revenue of EUR5.5M up 10% versus the same quarter last year (Q3 2005) resulting in year-to-date 2006 revenues of EUR15.0M up 12% versus the same period in 2005.
Highlights of the third quarter include:
- Year on year group revenue growth of 12% -- driven by strong re-order levels and new business wins across Europe and Asia in both the Woundcare and Oralcare businesses
- Woundcare technology breakthroughs:
Following the additional new healing and anti microbial benefits from our m.doc(TM) stops bleeding technology proven earlier this year, preclinical trials have now confirmed wound and dermal healing properties in a number of our finalised product delivery systems which will form the core of a new healing range:
- A new stops bleeding gel product has been successfully developed and following successful regulatory approval in the EU is being launched by the existing consumer first aid brand leader in a major EU market in Q4.
- A new range of stops bleeding blotters(TM) (thin film) first-aid and grooming products featuring new customized shapes and significantly enhanced packaging is currently in final stages of development and is being presented to potential partners in Q4.
- In a separate announcement today, Alltracel launched NANOPEUTICS Sro. a technology and business development joint venture with Elmarco, dedicated to the commercialization of the patented Nanospider(TM) based technology solutions. This joint venture will focus on the global professional and consumer woundcare markets and will provide Alltracel with a strong platform to drive it’s advanced woundcare business.
- Cardiovascular Health commercial progress:
In Q2, we completed sterol and statin pre-clinical trials confirming successful combination results of Alltracel’s bioactive for the cardiovascular health marketplace. Our commercialisation discussions continue to advance and we anticipate announcing our strategy to enter into the functional foods marketplace by year end.
- Oralcare progress:
Strong levels of re-orders from all geographies
Alltracel’s Chief Executive Officer, Tony Richardson, commented:
“We are pleased with this quarter’s revenue result which now brings year-to-date revenue up to EUR15M, 12% ahead of last years level. As well as re-orders from current customers, particularly in oralcare, as expected this quarter saw the start of Asia woundcare shipments following regulatory clearances secured in China and Japan. We remain confident in the outlook for the final quarter and are comfortable with analysts’ expectations of the business reaching full year profitability by year end.
""Overall we are looking forward to a strong final quarter both financially and through new product agreements and new partner agreements. We remain focussed on building sustainable profitable revenue through managing our cost base carefully while continuing to drive growth organically through new partnerships and technology developments in the woundcare, oralcare and CVH sectors, as well as appropriate acquisitions.”
For Further Information Contact: Dublin: Denise Cronin, Alltracel: +353-1-235-2162, press@alltracel.com London: Deborah Scott, Financial Dynamics: +44-(0)207-831-3113 New York: Sean Leous, Financial Dynamics: +1-212-850-5626 Notes to Editors:
Alltracel (AIM: AP.L) (www.alltracel.com) Alltracel Pharmaceuticals Plc is a Medical Technology Company focussed on the Woundcare, Oralcare and Cardiovascular Health markets.
With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel was founded in 1996 and listed on London’s Alternative Investment Market in July 2001.
Alltracel’s has a number of patents in the areas of polysaccharide manipulation and PTFE processes and products as well as a significant collaborative R&D programme in place focussed on its markets.
In the Woundcare market m-doc(TM) (Micro Dispersed Oxidized Cellulose; (www.m-doc.com)) is the trading name given to Alltracel’s patented technology which is proven as an effective and efficient haemostatic (blood-stopping) agent.
- In the consumer Woundcare sector m-doc(TM) is currently being marketed as the leading stops bleeding ingredient brand within recognized woundcare, and relevant first-aid brands worldwide.
- Alltracel’s woundcare technology is also currently poised for entry into the professional Woundcare and specialist Oralcare markets.
Within the Cardiovascular Health market Alltracel (www.alltracelcvh.com) has developed a novel bioactive compound that, following two years of scientific research including in vitro, pre-clinical and clinical trials indicates cardiovascular health (CVH) benefits on its own and in combination with existing CVH products.
Alltracel’s patented process utilises a derivative of cellulose fibre to produce a bioactive with scientifically proven properties that aid CVH; specifically lowering LDL cholesterol, reducing blood glucose levels and helping to prevent arterial plaque build up.
The end result is a pioneering, value-adding bioactive that can enhance and differentiate current cardiovascular health products and that can add benefit to current non-health benefiting nutritious finished foods.
- Further efficacy, dosage, timing/phasing and combination (with other bio-actives) studies to determine optimum delivery systems, formats and combinations in both the functional foods and pharmaceutical markets are underway.
- Development discussions with potential partners in the functional foods and pharmaceutical sectors in the EU, Asia and North America have commenced.
m-doc(TM) is a trademark of Alltracel Pharmaceuticals PLC.
blotters(TM) is a trademark of Alltracel Pharmaceuticals PLC.
Alltracel Pharmaceuticals Plc.
CONTACT: For Further Information Contact: Dublin: Denise Cronin,Alltracel: +353-1-235-2162, press@alltracel.com. London: Deborah Scott,Financial Dynamics: +44-(0)207-831-3113. New York: Sean Leous, FinancialDynamics: +1-212-850-5626
